The need for early markers in Alzheimer’s disease
Currently, there are no definitive early markers for Alzheimer’s disease (AD) or senile dementia of the Alzheimer type (SDAT). Nonetheless, there are some interesting marker candidates under evaluation. Several examples of candidate markers are considered in this review, including some biochemical, genetic, pharmacological, neuroimaging, and clinical measures. These examples are chosen to illustrate some aspects of an ideal marker, as well as the needs for such markers in different areas of AD and SDAT research and treatment.
KeywordsSingle Photon Emission Compute Tomography Alzheimer Patient Discriminant Function Analysis Cerebral Blood Flow Measurement Elderly Depressed Patient
Unable to display preview. Download preview PDF.
- Aigner TG, Mitchell SJ, Aggleton JP, DeLong MR, Struble RG, Price DL,Wenk GL, Mishkin M (1987) Effects of scopolamine and physostigmine on recognition memory in monkeys with ibotenic-acid lesions of the nucleus basalis of Meynert. Psychopharmacology 92: 292–300Google Scholar
- Brayne C, Calloway P (1988) Normal ageing, impaired cognitive function, and senile dementia of the Alzheimer’s type: a continuum? Lancet is 1265–1267Google Scholar
- Cutler NR (1988 a) Utility of biologic markers in the evaluation and diagnosis of Alzheimer’s disease. Brain Dysfunction 1: 12–31Google Scholar
- Davies P, Maloney AJR (1976) Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet ii: 1403–1405Google Scholar
- Friedland RP, Brun A, Budinger TF (1985 a) Pathological and positron emis- sion tomographic correlations in Alzheimer’s disease. Lancet is 228Google Scholar
- Funsch D, Sunderland T, Lawlor BA, Molchan SE, Mellow AM, Tariot PN, Hill JL, Murphy DL (1989) Platelet MAO activity in Alzheimer patients, older depressives, and age-matched controls. Society of Biological Psychiatry, San Francisco, CA (Abstract )Google Scholar
- Kuhl DE, Small GW, Riege WH, Fujikawa DG, Metter EJ, Benson DF, Ashford JW, Mazziotta JC, Maltese A, Dorsey DA (1987) Abnormal PET-FDG scans in early Alzheimer’s disease. J Nucl Med 28: 645 (Abstract)Google Scholar
- Post F (1975) Dementia, depression, and pseudo-dementia. In: Benson DF, Blumer D (eds) Psychiatric aspects of neurologic disease. Grune and Stratton, New York, pp 99–120Google Scholar
- Risberg J, Gustafson L (1983) Xe cerebral blood flow in dementia and in neuropsychiatry research. In: Magistretti P (ed) Functional radionuclide imaging of the brain. Raven Press, New YorkGoogle Scholar
- Roy BF, Sunderland T, Dauphin MM, Goodman A, Frazier JS, Murphy DL, Morihisa JM (in press) Human antibody to nerve growth factor: a preliminary study with implications for Alzheimer’s disease. Ann NeurolGoogle Scholar
- Wells CE (1979) Pseudodementia. Am J Psychiatry 136: 895–900Google Scholar
- Weinberger DR, Gibson RE, Coppola R, Jones DW, Berman KF, Braun AR, Zeeberg BR, Sunderland T (1989) 123IodoQNB SPECT in Alzheimer’s and Pick’s diseases. American Psychiatric Association, San Francisco, CA (Abstract )Google Scholar